| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.68B | — | +17.9% |
| Cost of Revenue | $581.0M | — | +14.8% |
| R&D Expense | $638.0M | — | +12.3% |
| SG&A Expense | $296.0M | — | +0.7% |
| Operating Income | $86.0M | — | +126.3% |
| Pre-tax Income | $281.0M | — | +62.4% |
| Income Tax | $121.0M | — | +536.8% |
| Net Income | $160.0M | — | +3.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.04B | +7.3% | -7.4% |
| Short-term Investments | $4.97B | +11.5% | +27.6% |
| Accounts Receivable | $191.0M | +2.7% | — |
| Current Assets | $23.60B | +25.6% | +10.8% |
| Total Assets | $26.83B | +20.8% | +7.1% |
| Current Liabilities | $16.36B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $1.71B | — | -4.5% |
| Investing Cash Flow | -$461.0M | — | -205.3% |
| Financing Cash Flow | $2.97B | — | +38.5% |
| -2.2% |
| Long-term Debt | $2.48B | — | — |
| Total Liabilities | $19.19B | +37.0% | +12.1% |
| Stockholders' Equity | $7.64B | -6.9% | -3.8% |